Posted on August 15, 2022 by Hokkaido NewsACTG announces launch of ACTIV-2d, a global phase 3 trial of the novel investigational COVID-19 oral antiviral agent S 217622 – EurekAlert ACTG announces launch of ACTIV-2d, a global phase 3 trial of the novel investigational COVID-19 oral antiviral agent S 217622 EurekAlert
